Regulation of B cell function by the immunosuppressive agent leflunomide

Transplantation

Volumn 61, Issue 4, 1996, Pages 635-642

  Siemasko, Karyn F ^a   Chong, Anita S F ^a   Williams, James W ^a   Bremer, Eric G ^a   Finnegan, Alison ^a  

^a Dept of Immunology/Microbiology ^*

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CELL CYCLE; CELL DIVISION; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED STRAINS; STIMULATION, CHEMICAL; T-LYMPHOCYTES; TIME FACTORS;

EID: 0029913383     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602270-00020     Document Type: Article

References (28)

1. Bartlett RR, Mattar T, Weithmann U, Anagnostopulos H, Popovic S, Schleyerbach R. Leflunomide (HWA486): a novel immunorestoring drug. In: Lewis AJ, Doherty NS, Ackerman NR. Therapeutic approaches to inflammatory diseases. New York: Elsevier, 1989: 215.
2. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity: I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985; 7: 7.
3. Popovic S, Bartlett RR. Disease modifying activity of HWA 486 on the development of SLE/1-mice. Agents Actions 1986; 19: 313.
4. Bartlett RR, Popovic S, Raiss RX. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol 1988; 75: 290.
5. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32: 10.
6. Kuchle CA, Toenes GH, Langer KH, Schorlemeer HU, Bartlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23: 1083.
7. Williams JW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation: control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporin. Transplantation 1994; 57: 1223.
8. Xiao F, Chong AS-F, Foster P, et al. Leflunomide controls rejection in hamster to rat cardiac xenografts. Transplantation 1994; 58: 826.
9. MacDonald AS, Sabr K, MacAuley MA, McALister VC, Bitter-Suermann H, Lee T. Effects of leflunomide and cyclosporin on aortic allograft chronic rejection in the rat. Transplant Proc 1994; 26: 3244.
10. Morris RE, Huang X, Cao W, Zheng B, Shorthouse RA. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc 1995; 27: 445.
11. Hodes RJ, Singer A. Cellular and genetic control of antibody responses in vitro: I. Cellular requirements for the generation of genetically controlled primary IgM responses to soluble antigens. Eur J Immunol 1977; 7: 892.
12. Golub ES. Brain-associated theta antigen: Reactivity of rabbit anti-mouse brain with mouse lymphoid cells. Cell Immunol 1971; 2: 353.
13. Tanguay DA, Chiles TC. Cell cycle-specific induction of Cdk2 expression in B lymphocytes following antigen receptor cross-linking. Mol Immunol 1994; 31: 643.
14. Pozzan T, Arslan P, Tsien RY, Rink TJ. Anti-immunoglobulin, cytoplasmic free calcium, and capping in B lymphocytes. J Cell Biol 1982; 94: 335.
15. Klaus GGB, O'Garra A, Bijsterbosch MK, Holman M. Activation and proliferation signals in mouse B cells: VIII. Induction of DNA synthesis in B cells by a combination of calcium ionophores and phorbol myristate acetate. Eur J Immunol 1986; 16: 92.
16. Bijsterbosch MK, Meade CJ, Turner GA, Klaus GGB. B lymphocyte receptors and phosphoinositide degradation. Cell 1985; 41: 999.
17. Cao W, Kao P, Xu J, Chao A, Gardner P, Morris R. Molecular mechanism of lymphocyte specific anti-proliferative action of leflunomide, a novel and effective immunosuppressant. FASEB J 1995; 9: A1370.
18. Zielinski T, Zeitter D, Müllner S, Bartleett RR. Leflunomide, a reversible inhibitor of pyrimidine biosynthesis? Inflamm Res (in press).
19. Schwartsmann G, Peters GJ, Laurensse E, et al. DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects. Biochem Pharmacol 1988; 137: 3257.
20. Chong AS-F, Finnegan A, Jiang XL, et al. Leflunomide, a novel immunosuppressive agent: the mechanism of inhibition of T cell proliferation. Transplantation 1993; 55: 1361.
21. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS-F. Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 1995; 270: 12,398.
22. DeFranco AL. Tyrosine phosphorylation and the mechanism of signal transduction by the B-lymphocyte antigen receptor. Eur J Biochem 1992; 210: 381.
23. Bartlett RR, Anagnostopulos H, Zielinski T, Mattar T, Schleyerbach R. Effects of leflunomide on immune responses and models of inflammation. Springer Semin Immunopathol 1993; 14: 381.
24. Zielinski T, Hermann M, Müller H-J, Riedel N, Bartlett RR. The influence of leflunomide on cell cycle, IL-2-receptor (IL-2-R) and its gene expression. Agents Actions 1994; 41: C204.
25. Chen SF, Ruben RL, Dexter DL. Mechanisms of action of the novel anti-cancer agent 6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4- quinolinecarboxylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis. Cancer Res 1986; 46: 5014.
26. Makowka L, Chapman F, Cramer DV. Historical development of brequinar sodium as a new immunosuppressive drug for transplantation. Transplant Proc 1993; 25: 2.
27. Bartlett RR, Campion G, Musikic P, et al. In: Lewis AJ, Furst DE, eds. Nonsteroidal anti-inflammatory drugs: mechanisms and clinical uses. New York: Dekker, 1994: 349.
28. Mattar T, Kochlar K, Bartlett R, Bremer EG, Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993; 334: 161.